Seminario Prof. Gerrit Borchard
26 gennaio 2015
SUPSI Dipartimento tecnologie innovative, Sala Anfiteatro
Il Laboratorio di tecnologie biomedicali e farmaceutiche avrà il piacere di ospitare, lunedì 26 gennaio, il Prof. Gerrit Borchard della Geneva-Lausanne School of Pharmacy (EPGL). Il seminario si concentrerà sugli aspetti scientifici e regolamentativi legati a medicinali biologicamente non complessi. L'evento si terrà in lingua inglese ed è gradita l'iscrizione all'indirizzo e-mail: andrea.danani@supsi.ch

Abstract (in lingua inglese)

Non-biological complex drugs (NBCDs) comprise different nanomedicine types such as glatiromoids, liposomes, micelles or nanoparticles. The complexity of such drugs results form the pharmacological activity being depended on both, the active principle as well as the vector system. Most NBCDs are prone to be recognized by the immune system, including activation of opsonization and capture by the reticuloendothelial system (RES), or activation of the innate immune system through pathogen-pattern recognition receptors (PRR). Distribution and deposition of nanomedicines in the body, unlike drugs of small molecular weight, therefore to some extent depends on recognition by and interaction with the immune system. Recognition is largely determined by processes involving the surface of the particulate nanomedicines. By altering the surface properties the attempt could be made to modify the way nanomedicines are interacting with the immune system, e.g., prolong time to recognition (stealth effect) or targeting to specific cell populations. A rational approach would be to identify factors (size, surface charge, hydrophilicity, guided opsonization) that need to be modified to achieve an intended effect. To achieve this goal, a deep understanding of both the physicochemical properties of NBCDs, as well as mechanisms involved in immune recognition are essential and need to be combined. NBCDs have been under investigation for several decades, and a few have actually matured to clinical application and entered the market in the absence of a dedicated regulatory approach. While analytical techniques describing the physicochemistry of these systems are being constantly refined, we had to understand that these systems need a multi-pronged analytical approach to describe their physicochemical properties. However, little is known on the relation between these properties and the clinical outcome, such that these systems always need a clinical assessment to ensure efficacy and safety. An effort is needed to discover these relations between nano-properties and biological activity, develop suitable analytical techniques and define specifications, establish clinical protocols and, last not least, integrate this knowledge in a science-based regulatory approach to NBCDs.

Bio (in lingua inglese)

Prof. Gerrit Borchard is a licensed pharmacist and obtained his Ph.D. in pharmaceutical technology from the University of Frankfurt (Germany). After holding several academic posts, including a lecturer position at Saarland University (Germany) and an Assistant and Associate Professorship at Leiden University (The Netherlands), he joined Enzon Pharmaceuticals, Inc. (USA) as Vice President Research. In 2005, he was appointed Full Professor of Biopharmaceutical Sciences at the University of Geneva (Switzerland), and Scientific Director of the Centre Pharmapeptides in Archamps (France), an international center for biopharmaceutical research and training. In 2008, Prof. Borchard was elected Vice President of the School of Pharmaceutical Sciences Geneva-Lausanne. He is President of the Swiss Society of Pharmaceutical Sciences (SSPhS) and Vice President of the Executive Committee of the European Federation of Pharmaceutical Sciences (EUFEPS).

Contatti
st.wwwsupsi@supsi.ch